The stock market is down Thursday, with the Dow Jones Industrial Average down 0.23%, the Nasdaq down 0.18% and the S&P 500 down 0.16%. Today’s winners include a pharmaceutical company that is getting bought out and a biotechnology company beating earnings expectations. Today’s losers are both pharmaceutical companies — one reported poor results for a drug trial and another reported weak third-quarter earnings.
These are Thursday’s market winners and losers.
Biggest Winners
Shares of DUSA Pharmaceuticals Inc. (NASDAQ: DUSA) are up 38.04% to $7.98 on trading volume of 4.4 million shares. Sun Pharmaceutical Inc. will buy the dermatology company for $230 million. Before Thursday, the 52-week high was $7.33.
Shares of InterMune Inc. (NASDAQ: ITMN) are up 15.32% to $9.41 on trading volume of 2.1 million shares. Although the biotechnology company lost 70 cents a share in the third quarter, it was better than the 90 cents a share that Wall St. analysts had estimated. The 52-week high is $21.90.
Biggest Losers
Shares of Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX) are down 60.22% to 58 cents on trading volume of 5.5 million shares. The company announced that its clinical trial for a drug to help treat cocaine addiction failed to meet its goal. The 52-week low is 50 cents.
Shares of Savient Pharmaceuticals Inc. (NASDAQ: SVNT) are down 19.29% to $1.13 on trading volume of 1.5 million shares. The company reported a loss of 56 cents a share, worse than the 48 cents a share Wall St. had expected. The 52-week low is 48 cents.
Samuel Weigley
Follow him on Twitter: SWeigley
Find a Qualified Financial Advisor (Sponsor)
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.